Minetta C. Liu
YOU?
Author Swipe
View article: 33 Tumor-informed circulating tumor DNA assay as a prognostic tool for detecting relapse in patients with non-small cell lung cancer receiving curative treatment
33 Tumor-informed circulating tumor DNA assay as a prognostic tool for detecting relapse in patients with non-small cell lung cancer receiving curative treatment Open
View article: 46 Association of longitudinal ctDNA dynamics with clinical outcomes in advanced urothelial carcinoma treated with enfortumab vedotin ± pembrolizumab: a real-world cohort study
46 Association of longitudinal ctDNA dynamics with clinical outcomes in advanced urothelial carcinoma treated with enfortumab vedotin ± pembrolizumab: a real-world cohort study Open
View article: Supplementary Figure S2 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Supplementary Figure S2 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities Open
Supplementary Figure S2 Transcriptomic level comparisons of the tumor compartment between MRD and IDS samples using GeoMx data. (A) Volcano plot showing DEGs between the tumor compartment of MRD and IDS samples, with genes related to hypox…
View article: Supplementary Table S4 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Supplementary Table S4 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities Open
Supplementary Table S4. Clinical Information of Translational Samples
View article: Supplementary Table S3 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Supplementary Table S3 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities Open
Supplementary Table S3. Multivariable Analysis of Prognostic Factors for Progression-Free Survival
View article: Data from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Data from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities Open
Purpose:Minimal residual disease (MRD) after first-line treatment of advanced-stage ovarian cancer remains a long-standing barrier to cure. We investigated the prognostic and translational value of MRD detection by second-look laparoscopy …
View article: Supplementary Figure S1 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Supplementary Figure S1 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities Open
Supplementary Figure S1 Clinical management of patients in the study cohort following SLL. *Many of these patients had the HRD assay performed retroactively on archival tissue and in this case, HRD status was not known in the upfront maint…
View article: Supplementary Table S2 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Supplementary Table S2 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities Open
Supplementary Table S2. Demographic and Clinical Characteristics for Patients Who Underwent Second Look Laparoscopy and Circulating Tumor DNA (ctDNA) Analysis
View article: Supplementary Figure S3 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Supplementary Figure S3 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities Open
Supplementary Figure S3 Clinical courses of MRD+ cases and tumor expression profiles in MRD lesions. (A) The expression of potential therapeutic targets and genes of interest in the tumor region of sample 3A, the MRD sample from Pt-10. (B)…
View article: Supplementary Table S1 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Supplementary Table S1 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities Open
Supplementary Table S1. CODEX Panel
View article: Supplementary Figure S4 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Supplementary Figure S4 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities Open
Supplementary Figure S4 Immune exclusion in the SLL sample 6B revealed by orthogonal spatial profiling. (A) CODEX profiling revealed two representative regions in the MRD sample (6B) of Pt-67. Region 1 located in the tumor margin where tum…
View article: Supplementary Table S5 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Supplementary Table S5 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities Open
Supplementary Table S5. Progressively Upregulated or Downregulated Genes in the Tumor Compartment of MRD+ Cases
View article: Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery
Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery Open
Objective: To evaluate the prognostic utility of postoperative circulating tumor DNA (ctDNA) for recurrence and treatment response in patients with rectal cancer undergoing upfront surgery. Summary Background Data: ctDNA-based molecular re…
View article: Using Circulating Tumor DNA–Based Molecular Residual Disease Detection for Postoperative Monitoring in Early-Stage Uterine Cancer
Using Circulating Tumor DNA–Based Molecular Residual Disease Detection for Postoperative Monitoring in Early-Stage Uterine Cancer Open
PURPOSE Clinical decision making for adjuvant treatment in early-stage uterine cancer (UC) following surgery is typically directed by clinicopathological risk factors. There is an unmet need for a clinically relevant biomarker to improve i…
View article: Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapy
Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapy Open
Background Circulating tumor DNA (ctDNA) is a promising intermediate end point for oncology drug development, potentially accelerating regulatory approvals by providing early insights into treatment response. However, challenges remain in …
View article: Longitudinal ctDNA Surveillance in Older Women with ER+ Breast Cancer to Facilitate Surgical De-Escalation: A Prospective, Hybrid-Decentralized Trial with Correlative Studies
Longitudinal ctDNA Surveillance in Older Women with ER+ Breast Cancer to Facilitate Surgical De-Escalation: A Prospective, Hybrid-Decentralized Trial with Correlative Studies Open
For older patients with competing comorbidities, optimizing oncologic therapies is of paramount importance. Circulating tumor DNA (ctDNA) is a validated prognostic factor across solid tumors and may provide a strategy to identify patients …
View article: Tumor-Informed ctDNA Assay to Predict Outcome in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with PD-1 Inhibitor
Tumor-Informed ctDNA Assay to Predict Outcome in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with PD-1 Inhibitor Open
Purpose: Although immunotherapy improves the overall survival (OS) of patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN), only 15% to 20% of patients derive a long-term benefit. We hypothesized th…
View article: Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer
Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer Open
Objective: In this study, we evaluate the utility of ctDNA analysis in a large cohort of patients for whom ctDNA testing was ordered commercially with real-world application. Summary Background Data: Circulating tumor DNA (ctDNA) has emerg…
View article: Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities Open
Purpose: Minimal residual disease (MRD) after first-line treatment of advanced-stage ovarian cancer remains a long-standing barrier to cure. We investigated the prognostic and translational value of MRD detection by second-look laparoscopy…
View article: Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker study
Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker study Open
Patients with locally advanced resectable (LAR) gastric/gastroesophageal junction (G/GEJ) adenocarcinomas have a high recurrence risk despite pre- and post-operative treatment. In the PLAGAST prospective study (NCT02674373), we investigate…
View article: Peripheral blood gene expression signatures of systemic immunity predict tumor microenvironment biology and therapeutic response in breast cancer
Peripheral blood gene expression signatures of systemic immunity predict tumor microenvironment biology and therapeutic response in breast cancer Open
View article: Feasibility of Personalized and Tumor-Informed Circulating Tumor DNA Assay for Early Recurrence Detection in Patients With Hepatocellular Carcinoma
Feasibility of Personalized and Tumor-Informed Circulating Tumor DNA Assay for Early Recurrence Detection in Patients With Hepatocellular Carcinoma Open
PURPOSE Hepatocellular carcinoma (HCC) has high relapse rates after standard-of-care (SOC) resection or liver transplantation (LT). We evaluated the utility of circulating tumor DNA (ctDNA) to predict relapse/progression risk in patients w…
View article: Supplementary Methods S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Methods S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Methods 1
View article: Supplementary Table S6 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S6 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 6: Comparisons of the probabilities of patients that are CTC positive at baseline being a CTC responder (i.e., switching from CTC positive at baseline to CTC negative at first follow-up) between HER2-positive/hormone re…
View article: Supplementary Figure S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Figure S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Figure 1. Diagram showing patient disposition.
View article: Data from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Data from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Purpose:The aim of PREDICT was to confirm clinical validity and the potential for clinical utility of serial circulating tumor cell (CTC) enumeration in patients with metastatic breast cancer, focusing on its prognostic value in different …
View article: Supplementary Table S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 1. Clinical trials, multicenter studies, and institutions/centers that provided data sets from MBC patients for the pooled analysis.
View article: Supplementary Figure S3 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Figure S3 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Figure 3: Kaplan-Meier plots of overall survival (OS) according to CTC status at baseline for HER2-positive/hormone receptor-positive tumors(A, B) and HER2-positive/hormone receptor-negative tumors(C, D). Survival time is giv…
View article: Supplementary Table S7 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S7 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 7. Median overall survival (OS) and hazard ratios for the CTC change groups as categorized based on the ≥5 CTC cutoff for CTC positivity (reference group neg/neg) for patients with hormone receptor-positive/HER2-negativ…
View article: Supplementary Table S2 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S2 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 2. Absolute and relative frequencies of CTC change groups and percentage of CTC responders (as categorized according to the ≥1 CTC or ≥5 CTC cutoff for CTC positivity) overall, according to tumor subtypes and according …